Scarica l'app Stockscreener
1.12
1.82%
0.02
Precedente Chiudi:
$1.10
Aprire:
$1.1
Volume 24 ore:
9,926
Relative Volume:
0.42
Capitalizzazione di mercato:
$36.04M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-3.2175
EPS:
-0.3481
Flusso di cassa netto:
-
1 W Prestazione:
-0.88%
1M Prestazione:
-3.45%
6M Prestazione:
-3.26%
1 anno Prestazione:
-71.95%
Intervallo 1D:
$1.10
$1.12
Intervallo di 1 settimana:
$1.10
$1.15
Portata 52W:
$0.85
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(646) 350-0702
Indirizzo
22 BOSTON WHARF ROAD, BOSTON
Confronta AKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.12 | 35.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Maxim Group | Buy |
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics appoints new head of oncology business By Investing.com - Investing.com India
Akari Therapeutics appoints new head of oncology business - Investing.com
Akari Therapeutics' New CEO Reveals Future Roadmap: Key Insights from First Leadership Address - Stock Titan
Akari Therapeutics Advances ADC Development Amid Financial Challenges - TipRanks
Akari Therapeutics Transforms: Next-Gen Cancer Drug Shows Promise Amid 2024 Results - Stock Titan
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com India
Acciones de Alibaba (BABA) caen tras medidas de Trump para frenar inversiones chinas en tecnología - Yahoo Finanzas
Citi reveló que Ecopetrol ha publicado la guía de sus resultados para el cuarto trimestre de 2024 - Yahoo Finanzas
Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status - StockTitan
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Riesgos y oportunidades sobre el futuro de la cotización de YPF - Yahoo Finanzas
¿Qué empresas del Ibex 35 también cotizan fuera de España? - Yahoo Finanzas
Bancolombia inicia programa para aumentar la liquidez de sus acciones - Yahoo Finanzas
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Trending UK-Based Penny Stock Picks 2024 - timothysykes.com
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
Las 100 empresas latinoamericanas que se han lanzado a conquistar Wall Street - Yahoo Finanzas
Tras filtración de datos, las acciones de Globant se hundieron 10% - Yahoo Finanzas
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics PLC Stock Price Today | NASDAQ: AKTX Live - Investing.com
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Non sono disponibili dati finanziari per Akari Therapeutics Plc Adr (AKTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):